Patent application number | Description | Published |
20120014169 | NON-VOLATILE DATA-STORAGE LATCH - One embodiments of the present invention is directed to a single-bit memory cell comprising transistor-based bit latch having a data state and a memristor, coupled to the transistor-based bit latch, in which the data state of the transistor-based bit latch is stored by a store operation and from which a previously-stored data state is retrieved and restored into the transistor-based bit latch by a restore operation. Another embodiment of the present invention is directed to a single-bit memory cell comprising a master-slave flip flop and a slave flip flop, and a power input, a memristor, a memory-cell power input, a first memory-cell clock input, a second memory-cell clock input, a memory-cell data input, a memory-cell data output, and two or more memory-cell control inputs. | 01-19-2012 |
20130028004 | REFRESHING MEMRISTIVE SYSTEMS - A method for operating a circuit ( | 01-31-2013 |
20130121054 | THREE-DIMENSIONAL INTEGRATED CIRCUIT - A three-dimensional integrated circuit comprising a submicroscale integrated-circuit substrate and n nanoscale layers stacked above the submicroscale integrated-circuit substrate, a nanowire-junction memory element in each of which is independently controlled by two submicroscale subcomponents within the submicroscale integrated-circuit substrate, the first submicroscale subcomponent coupled through a first set of switches to each of the n nanowire-junction memory elements and the second submicroscale subcomponent coupled through a second set of switches to each of the n nanowire-junction memory elements, the total number of switches in the first and second sets of switches less than 2n, and n greater than or equal to 2. | 05-16-2013 |
20130132314 | SYSTEMS AND METHODS FOR MODELING BINARY SYNAPSES - Methods and system for modeling the behavior of binary synapses are provided. In one aspect, a method of modeling synaptic behavior includes receiving an analog input signal and transforming the analog input signal into an N-bit codeword, wherein each bit of the N-bit codeword is represented by an electronic pulse ( | 05-23-2013 |
20150212862 | COMPILATION SYSTEM FOR EXECUTABLE OBJECTS - In one implementation, a compilation system identifies a plurality of objects within a description of an application, determines a plurality of state paths among the objects, and generates a plurality of executable objects that are independently executable and are each associated with a data structure representing a state of that executable object. Each state path is derived from an operation included in the description of the application on an object from the objects for which another object from the objects is an operand. Each executable object includes instructions that when executed at a host cause the host to perform an operation associated with that executable object and provide the state of that executable object to one or more other executable objects from the plurality of executable objects according to one or more state paths in response to a synchronization mechanism not defined within the description of the application. | 07-30-2015 |
Patent application number | Description | Published |
20110256635 | SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS - Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. | 10-20-2011 |
20120276551 | METHODS PREDICTING RISK OF AN ADVERSE CLINICAL OUTCOME - Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation 5 in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 and a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the in the methods described. | 11-01-2012 |
20130071404 | METHODS OF TREATING CARDIOVASCULAR DISEASES AND PREDICTING THE EFFICACY OF EXERCISE THERAPY - Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject. | 03-21-2013 |
20130177931 | SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS - Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. | 07-11-2013 |
20130244236 | PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS - Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure. | 09-19-2013 |
20130345805 | METHODS FOR TREATING OR PREDICTING RISK OF A VENTRICULAR TACHYARRHYTHMIA EVENT - Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods. | 12-26-2013 |
20140045200 | PREDICTING MORTALITY AND DETECTING SEVERE DISEASE - Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease. | 02-13-2014 |
20140051773 | METHODS FOR PREDICTING RISK OF DEVELOPING HYPERTENSION - Methods using biomarkers, e.g., serum levels of ST2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension. | 02-20-2014 |
20140058743 | Multimarker Risk Stratification - Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure. | 02-27-2014 |
20140234875 | Methods Predicting Risk of an Adverse Clinical Outcome - Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject. | 08-21-2014 |
20140286944 | Methods of Treating Cardiovascular Diseases and Predicting the Efficacy of Exercise Therapy - Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject. | 09-25-2014 |
20140302536 | DIAGNOSIS OF PULMONARY AND/OR CARDIOVASCULAR DISEASE - Described are methods and kits for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject using ST2/Interleukin 1 Receptor Like 1 (IL1RL1) and/or Interleukin 33 (IL-33), and a biomarker for CVD, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-Terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP. | 10-09-2014 |
20150081224 | PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS - Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure. | 03-19-2015 |
20150199491 | METHODS AND SYSTEMS FOR DETERMINING RISK OF HEART FAILURE - Provided are methods, algorithms, nomograms, and computer/software systems that can be used to accurately determine the risk of developing heart failure within a specific time period in a subject not diagnosed or presenting with heart failure. Also provided are methods, algorithms, nomograms, computer/software systems for selecting a treatment for a subject and determining the efficacy of a treatment for reducing the risk of heart failure in a subject. | 07-16-2015 |
20150361177 | SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS - Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. | 12-17-2015 |
Patent application number | Description | Published |
20090264779 | PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS - Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure. | 10-22-2009 |
20090305265 | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PROGNOSIS OF CARDIOVASCULAR DISEASE - The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pancarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis). | 12-10-2009 |
20100009356 | DIAGNOSIS OF CARDIOVASCULAR DISEASE - This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function. | 01-14-2010 |
20100055683 | DIAGNOSIS OF PULMONARY AND/OR CARDIOVASCULAR DISEASE - Described are methods and kits for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject using ST2/Interleukin 1 Receptor Like 1 (IL1RL1) and/or Interleukin 33 (IL-33), and a biomarker for CVD, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-Terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP. | 03-04-2010 |
20110053170 | Interleukin-33 (IL-33) for the Diagnosis and Prognosis of Cardiovascular Disease - The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pericarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis). | 03-03-2011 |
20110262941 | PREDICTING MORTALITY AND DETECTING SEVERE DISEASE - Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease. | 10-27-2011 |
20120040381 | PREDICTING MORTALITY AND DETECTING SEVERE DISEASE - Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease. | 02-16-2012 |
20120065897 | PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS - Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure. | 03-15-2012 |